The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
The company has also achieved a CE-IVD mark for its HemeAccuTest, which targets hematological malignancies.
The company plans to use the funds to drive commercialization of its recently launched Fluidity One instrument and develop other products in its pipeline.
The company is developing a single-molecule sequencing technology intended to significantly reduce the cost and improve the accuracy of sequencing.
The company said it will use the funds to expand its operations in Ireland, which it established through the recent acquisition of Genomics Medicine Ireland.
The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.
The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.
The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.